FDA OK's Omeros cataract surgery drug Omidria; eyes on pricing
This article was originally published in Scrip
Executive Summary
With the FDA's approval in hand for Omidria (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement (ILR), all eyes are now on the drug's pricing and launch, which is anticipated late summer or early fall.
You may also be interested in...
Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.